UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 --


-- ENVISION Showed a Complete Response...

Related Keywords

Israel ,Liz Barrett ,Urogen Rtgel ,Sandip Prasad ,Nasdaq ,Urogen Pharma Ltd ,Twitter ,Company Investor Relations ,Drug Administration ,Morristown Medical Center Atlantic Health System ,Urogen Pharma ,New Drug Application ,Chief Executive Officer ,Genitourinary Surgical Oncology ,Morristown Medical ,Atlantic Health System ,Investor Relations ,Private Securities Litigation Reform Act ,Risk Factors ,Quarterly Report ,Markets ,